Impact of a pharmacist-driven methicillin-resistant Staphylococcus aureus surveillance protocol

American Journal of Health-System Pharmacy

Volumn 74, Issue 21, 2017, Pages 1765-1773

  Willis, Courtney ^a   Allen, Bryan ^a   Tucker, Calvin ^a   Rottman, Kathleen ^a   Epps, Kevin ^a  

^a St Vincent's Medical Center Jacksonville   (United States)

Author keywords

Methicillin resistant staphylococcus aureus; Pneumonia; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL OUTCOME; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG USE; FEMALE; HOSPITAL MORTALITY; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; NOSE SMEAR; OUTCOME ASSESSMENT; PHARMACIST; PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; QUASI EXPERIMENTAL STUDY; RETROSPECTIVE STUDY; SCOPE OF PRACTICE; SCREENING; TREATMENT DURATION; AGED; COMPLICATION; HOSPITAL PHARMACY; MICROBIOLOGY; MIDDLE AGED; MORTALITY; NOSE CAVITY; STAPHYLOCOCCUS INFECTION; VANCOMYCIN RESISTANCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLINICAL PROTOCOLS; COHORT STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; LENGTH OF STAY; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NASAL CAVITY; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; POLYMERASE CHAIN REACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 85032492697     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp160964     Document Type: Article

References (28)

1. Garau J, Bouza E, Chastre J et al. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect. 2009; 15:125-36.
2. Gomes DM, Ward KE, La Plante KL. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus. Pharmacotherapy. 2015; 35:424-32.
3. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171: 388-416.
4. Kalil AC, Metersky ML, Klompas M et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016; 63:575-82.
5. Bauer KA, Perez KK, Forrest GN et al. Review of rapid diagnostic tests used by antimicrobial stewardship programs. Clin Infect Dis. 2014; 59(suppl 3): S134-S145.
6. Davis KA, Steward JJ, Crouch HK et al. Methicillin-resistant Staphylococcus aureus nares colonization at hospital admission and its effects on subsequent MRSA infection. Clin Infect Dis. 39:776-82.
7. Huang SS, Hinrichsen VL, Datta R et al. Methicillin-resistant Staphylococcus aureus infection and hospitalization in high-risk patients in the year following detection. PLoS ONE. 2011; 6:e24340.
8. Kelley PG, Grabsch EA, Howden BP et al. Comparison of the Xpert methicillin-resistant Staphylococcus aureus assay, BD Gene Ohm MRSA assay, and culture for detection of nasal and cutaneous groin colonization of MRSA. J Clin Microbiol. 2009; 47: 3769-72.
9. Jonas D, Speck M, Daschner FD et al. Rapid PCR-based identification of methicillin-resistant Staphylococcus aureus from screening swabs. J Clin Microbiol. 2002; 40:1821-3.
10. Wassenberg MW. Kluytmans JA, Box AT et al. Rapid screening of methicillin-resistant Staphylococcus aureus using PCR and chromogenic agar: A prospective study to evaluate costs and effects. Clin Microbiol Infect. 2010; 16175461.
11. Dangerfield B, Chung A, Webb B et al. Predictive value of methicillin-resistant Staphylococcus aureus nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother. 2014; 58:859-64.
12. Robicsek A, Suseno M, Beaumont J et al. Prediction of methicillin-resistant Staphylococcus aureus involvement in disease sites by concomitant nasal sampling. J Clin Microbiol. 2008; 46:588-92.
13. Johnson J, Wright ME, Sheperd L et al. Nasal methicillin-resistant Staphylococcus aureus polymerase chain reaction: A potential use in guiding antibiotic therapy for pneumonia. Perm J. 2015; 19:34-6.
14. Smith MN, Erdman MJ, Ferreira JA et al. Clinical utility of methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction assay in critically ill patients with nosocomial pneumonia. J Crit Care. 2017; 38:168-71.
15. Giancola SE, Nguyen AT, Le B et al. Clinical utility of a nasal methicillin-resistant Staphylococcus aureus polymerase chain reaction test in intensive and intermediate care unit patients with pneumonia. Diagn Microbiol Infect Dis. 2016; 86:307-10.
16. Boyce JM, Pop O, Abreu-Lanfranco O et al. A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia. Antimicrob Agents Chemother. 2013; 57:1163-8.
17. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43:925-42.
18. Tamma PD, Han JH, Rock C et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis. 2015; 60:1319-25.
19. Fridkin S, Srinivasan A. Implementing a strategy for monitoring inpatient antimicrobial use among hospitals in the United States. Clin Infect Dis. 2014; 58:401-6.
20. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44: S27-S72.
21. Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: A critical and comprehensive review. Clin Kidney J. 2013; 6:8-14.
22. SAS OnDemand for Academics: user's guide. Cary, NC: SAS Institute; 2015.
23. Segarra-Newnham M, Church TJ. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Ann Pharmacother. 2012; 46:1678-87.
24. Shorr AF, Myers DE, Huang DB et al. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis. 2013; 13:268 .
25. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharma cists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82-98.
26. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 166:2138-44.
27. Baby N, Faust AC, Smith T et al. Nasal methicillin-resistant Staphylococcus aureus (MRSA) PCR testing reduces the duration of MRSA-targeted therapy in patients with suspected MRSA pneumonia. Antimicrob Agents Chemother. 2017; 61: 02432-16.
28. Ide L, Lootens J, Thibo P. The nose is not the only relevant MRSA screening site. Clin Microbiol Infect. 2009; 15:1192-3.